Review articlePublished 7 Jul 2016
The rationale and evidence for triple antiplatelet therapy in acute coronary syndromes
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The platelet response to endothelial injury is central to the process of atherothrombosis, the pathophysiologic hallmark of acute coronary syndromes (ACS). Multiple antiplatelet agents have been developed to inhibit key components of this platelet activity. The use of two or more antiplatelet agents in patients with ACS reduces ischemic events but increases bleeding risk. Triple antiplatelet therapy utilizing aspirin, P2Y12 antagonists and glycoprotein IIb/IIIa inhibitors, remains indicated in select ACS populations. In ST-elevation myocardial infarction, triple antiplatelet therapy may be beneficial in subjects receiving percutaneous coronary intervention without adequate thienopyridine preloading and in those with large thrombus burden. In subjects with non-ST elevation ACS, triple antiplatelet therapy is reserved for those at highest ischemic risk (e.g., elevated troponin or refractory ischemia) and for those with thrombotic complications at the time of percutaneous coronary intervention. The focus of this review is to summarize the rationale and evidence supporting the use of triple antiplatelet therapies in the management of patients with ACS.
Keywords
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Investigation
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Beau M Hawkins”
- BylineArticles whose byline prints “Jorge F Saucedo”
- BylineArticles whose byline prints “Sunil V Rao”